Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Sees Large Growth in Short Interest

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) was the target of a large growth in short interest during the month of October. As of October 30th, there was short interest totaling 2,886 shares, a growth of 5,345.3% from the October 15th total of 53 shares. Based on an average daily volume of 1,238 shares, the short-interest ratio is currently 2.3 days. Currently, 0.0% of the company’s shares are sold short.

Orion OYJ Trading Down 1.9%

ORINY traded down $1.13 during mid-day trading on Tuesday, hitting $56.92. The stock had a trading volume of 290 shares, compared to its average volume of 1,176. The stock’s fifty day simple moving average is $49.48 and its 200-day simple moving average is $42.26. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.64 and a quick ratio of 1.48. The firm has a market capitalization of $16.07 billion, a price-to-earnings ratio of 21.00 and a beta of 0.05. Orion OYJ has a 1-year low of $33.62 and a 1-year high of $58.15.

Orion OYJ (OTCMKTS:ORINY) last announced its quarterly earnings results on Wednesday, October 28th. The company reported $0.68 earnings per share (EPS) for the quarter. Orion OYJ had a net margin of 30.25% and a return on equity of 54.09%. The company had revenue of $623.96 million during the quarter.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group upgraded Orion OYJ from a “hold” rating to a “strong-buy” rating in a report on Monday, October 26th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, Orion OYJ currently has an average rating of “Buy”.

Orion OYJ Company Profile

Orion Oyj is a Finnish pharmaceutical company that develops, manufactures and markets medicines for human and veterinary use. Its portfolio includes prescription and over-the-counter medicines, as well as active pharmaceutical ingredients supplied to other pharmaceutical companies. Founded in 1917 and headquartered in Espoo, Finland, Orion has a long history in the pharmaceutical industry. The company focuses on areas including oncology, neurology and respiratory diseases, and develops some products in collaboration with international pharmaceutical partners.